Presentation is loading. Please wait.

Presentation is loading. Please wait.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Published byMarybeth Atkins Modified over 6 years ago

Similar presentations

Presentation on theme: "Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung."— Presentation transcript:

1 Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)  Jacques Cadranel, MD, PhD, Audrey Mauguen, MSc, Michele Faller, MD, PhD, Gérard Zalcman, MD, PhD, Marie-Pierre Buisine, PharmD, PhD, Virginie Westeel, MD, PhD, Elisabeth Longchampt, MD, Marie Wislez, MD, PhD, Bruno Coudert, MD, Catherine Daniel, MD, Bruno Chetaille, MD, Stephane Michiels, PhD, Helene Blons, MD, PhD, Jerome Solassol, MD, Florence De Fraipont, PharmD, PhD, Pascal Foucher, MD, Thierry Urban, MD, PhD, Ludovic Lacroix, MD, PhD, Virginie Poulot, LabTec, Elisabeth Quoix, MD, PhD, Martine Antoine, MD, Guillaume Danton, LabTec, Franck Morin, Ms, BSc, Christos Chouaid, MD, PhD, Jean-Pierre Pignon, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 10, Pages (October 2012) DOI: /JTO.0b013e318265b2b5 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Flow chart. EGFR-TKI, epidermal growth factor tyrosine kinase inhibitor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Progression-free survival and overall survival curves for A, the clinical population (n = 522), and (B) biological population (n = 307). m, months. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Progression-free survival and (B) overall survival curves by mutation status. m, months. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 A, Regression tree for PFS and (B) PFS curves corresponding to the four final groups of the regression tree. PFS, progression-free survival; PS, performance status; HR, hazards ratio; m, months. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 A, Regression tree for OS and (B) OS curves corresponding to the five final groups of the regression tree. PS, performance status; HR, hazards ratio; OS, overall survival; m, months. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung."

Similar presentations

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France  Nicolas.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France  Nicolas.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer  Rodryg Ramlau, MD,

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer  Rodryg Ramlau, MD,
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers  Christos.

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers  Christos.
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of.

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele.
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Similar presentations

Ads by Google